NanoViricides shares are trading higher after the company reported effectiveness of antiviral drug candidate in animal model with respiratory syncytial virus infection.
Portfolio Pulse from Benzinga Newsdesk
NanoViricides reported effectiveness of its antiviral drug candidate in an animal model with respiratory syncytial virus infection, leading to a rise in its share prices.
July 11, 2023 | 4:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NanoViricides' shares are trading higher after positive results from its antiviral drug candidate in an animal model.
The positive results from the antiviral drug candidate indicate potential success in human trials, which could lead to increased revenues for the company. This positive news is likely to attract investors, leading to a rise in the company's share prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100